Frequency of S492R Mutations in the Epidermal Growth Factor Receptor: Analysis of Plasma Dna from Metastatic Colorectal Cancer Patients Treated with Panitumumab or Cetuximab Monotherapy
Kathryn J. Newhall(Amgen (United States)), R. Sidhu(Amgen (United States)), Marc Peeters(University of Antwerp), Attili Satya Suresh(Apollo Hospitals), J. Li(Fudan University), Stefano Cascinu(Vita-Salute San Raffaele University), Selam Ogbagabriel(Amgen (United States)), Sergei Tjulandin, Anne Thomas(Leicester Royal Infirmary), Timothy Price(Basil Hetzel Institute), Michael Boedigheimer(Amgen (United States)), T.W. Kim(Ulsan College), Sandra Sexson(Amgen (United States)), Swaminathan Murugappan(Amgen (United States)), K. Zhang(Amgen (United States)), Paul Ruff
Cited by 23
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Cetuximab for the Treatment of Colorectal Cancer
|New England Journal of Medicine|2007|1.8k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k